The Dyax-Jerini showdown

Locked in a race to market with Jerini AG with rival compounds to treat hereditary angioedema (HAE), Dyax Corp. had been aiming to submit a BLA for its DX-88 recombinant kallikrein inhibitor protein next year. DYAX now doesn't expect a submission until after 2005, but still contends it will be first to market, even though Jerini says it will submit its BLA by the end of next year.

Earlier

Read the full 699 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE